Engineered heparins as new anticoagulant drugs. Issue 1 (21st November 2016)

• Record Type: Journal Article
• Authors: Vaidyanathan, Deepika; Williams, Asher; Dordick, Jonathan S.; Koffas, Mattheos A.G.; Linhardt, Robert J.
• Is Part Of: Bioengineering & translational medicine. Volume 2:Issue 1(2017)
• Page Start: 17
• Page End: 30
• Publication Date: 2016-11-21
• Subjects: bioengineered -- chemoenzymatic synthesis -- glycosaminoglycans -- metabolic engineering; Bioengineering -- Periodicals; Drug development -- Periodicals; Drugs -- Testing -- Periodicals; 660.6
• DOI: 10.1002/btm2.10042
• Languages: English
• ISSNs: 2380-6761

Abstract

Abstract: Heparin is an anionic polysaccharide that is widely used as a clinical anticoagulant. This glycosaminoglycan is prepared from animal tissues in metric ton quantities. Animal‐sourced heparin is also widely used in the preparation of low molecular weight heparins that are gaining in popularity as a result of their improved pharmacological properties. The recent contamination of pharmaceutical heparin together with concerns about increasing demand for this life saving drug and the fragility of the heparin supply chain has led the scientific community to consider other potential sources for heparin. This review examines progress toward the preparation of engineered heparins through chemical synthesis, chemoenzymatic synthesis, and metabolic engineering.